OXcan Raises £9M Series A to Revolutionise Early Lung Cancer Detection

[James]

A Breakthrough in Early Cancer Detection

Oxford Cancer Analytics (OXcan), a pioneering medtech company, has secured £9 million in Series A funding to advance its mission of transforming early lung cancer detection. Led by We Venture Capital and Cross-Border Impact Ventures, the funding round also included participation from Eka Ventures, Civilization Ventures, DigitalDx Ventures, Macmillan Cancer Support, Aurelium Ventures, OKG Capital, and prominent angel investors. This investment brings OXcan’s total funding to date to £13.4 million (USD $16.7M).

 

 

OXcan’s Innovative Technology

1. Advanced Proteomics and AI

OXcan is at the forefront of cancer diagnostics, leveraging:

• Proteomics to identify biomarkers for early-stage lung cancer.

• AI-driven liquid biopsy tests to provide precise, minimally invasive solutions.

These innovations offer:

• Early detection of lung cancer when curative treatments are most effective.

• Cost-effective and scalable solutions for global healthcare systems.

2. Global Partnerships

OXcan collaborates with over 20 healthcare centres across three continents to:

• Build a robust biobank for diverse population studies.

• Deploy scalable diagnostics internationally.

3. Impact on Global Health

Lung cancer, the leading cause of cancer mortality globally, results in 1.8 million deaths annually. OXcan’s diagnostics aim to:

• Improve five-year survival rates by detecting cancer at earlier stages.

• Reduce healthcare burdens through timely intervention.

 

 

Key Developments and Strategic Appointments

Appointment of Dr. Heinrich Roder

Dr. Heinrich Roder, an expert in lung cancer proteomics, has joined OXcan as Senior Vice President of Research and Development. With over two decades of experience, Dr. Roder will:

• Lead the development of OXcan’s blood tests for lung cancer.

• Oversee the global deployment of the company’s diagnostic solutions.

Expansion of Leadership and Board

Gemma Sturt from We Venture Capital and Annie Theriault from Cross-Border Impact Ventures have joined OXcan’s Board of Directors, bringing valuable expertise in healthcare and diagnostics.

 

 

Statements from Leadership and Investors

Dr. Peter Jianrui Liu, Co-Founder & CEO

"Our vision is to revolutionise cancer detection through cutting-edge technology and global collaboration. This funding empowers us to improve patient outcomes by making early detection accessible and affordable worldwide."

Dr. Andreas Halner, Co-Founder & COO

"Early detection is essential for saving lives. With this investment, we are advancing our mission to offer minimally invasive, cost-effective diagnostics to global markets."

Gemma Sturt, Senior Investment Manager at We Venture Capital

"OXcan’s use of advanced proteomics and AI is setting a new benchmark in cancer diagnostics. We are thrilled to support their mission to improve patient outcomes through innovative technology."

Felix Litzkow, Head of Impact Investments at Macmillan Cancer Support

"OXcan’s low-cost, accurate blood test has the potential to transform lung cancer diagnosis and increase access to testing worldwide."

 

 

The Road Ahead for OXcan

Scaling Innovation

OXcan will utilise the £9M funding to:

• Expand its biobank and refine its biomarker discovery platform.

• Conduct large-scale clinical trials for its liquid biopsy tests.

• Commercialise its diagnostics globally.

Strengthening Global Impact

OXcan is working with lung cancer screening programs worldwide to:

• Integrate its tests into existing clinical pathways.

• Accelerate adoption in high-need populations.

• Reduce healthcare system burdens from late-stage cancer diagnoses.